rs373134168
Variant summary
Our verdict is Benign. Variant got -11 ACMG points: 0P and 11B. BP4_ModerateBP6_Very_StrongBP7
The NM_000059.4(BRCA2):c.6960G>A(p.Leu2320Leu) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000162 in 1,609,134 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★★).
Frequency
Consequence
NM_000059.4 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -11 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.6960G>A | p.Leu2320Leu | synonymous_variant | Exon 13 of 27 | 5 | NM_000059.4 | ENSP00000369497.3 | ||
BRCA2 | ENST00000530893.7 | c.6591G>A | p.Leu2197Leu | synonymous_variant | Exon 13 of 27 | 1 | ENSP00000499438.2 | |||
BRCA2 | ENST00000614259.2 | n.6960G>A | non_coding_transcript_exon_variant | Exon 12 of 26 | 2 | ENSP00000506251.1 |
Frequencies
GnomAD3 genomes AF: 0.000118 AC: 18AN: 152000Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000280 AC: 7AN: 249948Hom.: 0 AF XY: 0.00000740 AC XY: 1AN XY: 135166
GnomAD4 exome AF: 0.00000549 AC: 8AN: 1457134Hom.: 0 Cov.: 29 AF XY: 0.00000276 AC XY: 2AN XY: 724908
GnomAD4 genome AF: 0.000118 AC: 18AN: 152000Hom.: 0 Cov.: 32 AF XY: 0.0000943 AC XY: 7AN XY: 74230
ClinVar
Submissions by phenotype
not specified Benign:2
- -
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
not provided Benign:2
- -
- -
Hereditary cancer-predisposing syndrome Benign:2
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
Breast-ovarian cancer, familial, susceptibility to, 2 Benign:1
Synonymous substitution variant, with low bioinformatic likelihood to result in a splicing aberration (Splicing prior probability 0.02; http://priors.hci.utah.edu/PRIORS/). -
Malignant tumor of breast Benign:1
The BRCA2 p.Leu2320= variant was not identified in the literature nor was it identified in the following databases: COGR, Cosmic, BIC, ARUP Laboratories, or the Zhejiang Colon Cancer Database. The variant was identified in dbSNP (ID: rs373134168) “With Likely benign allele”, ClinVar (classified likely benign, reviewed by an expert panel (June 2017); submitters likely benign by ENIGMA, Ambry Genetics and Invitae and benign by GeneDx), Clinvitae (4x), UMD-LSDB (2x - 3-UV) and in control databases in 10 of 275770 chromosomes at a frequency of 0.00004 increasing the likelihood that this may be a low frequency variant in certain populations of origin (Genome Aggregation Consortium Feb 27, 2017). Breakdown of the observations by population include Latino in 6 of 34274 chromosomes (freq: 0.0002), European Non-Finnish in 4 of 126212 chromosomes (freq: 0.00003), while the variant was not observed in the African, Ashkenazi Jewish, East Asian, South Asian, and European Finnish populations. The p.Leu2320= variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. In addition, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. -
Hereditary breast ovarian cancer syndrome Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at